International Journal of
Reproductive Biomedicine
Wed, Jun 3, 2026
[Archive]
Volume 24, Issue 4 (April 2026)
IJRM 2026, 24(4): 337-348 |
Back to browse issues page
Ethics code: IR.UMSU.REC.1404.254
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Fayyazi Moghaddam S, Hajshafiha M, Behroozi Lak T, Sadeghpour S, Haghtalab A. Efficacy and safety of different cetrorelix doses in the luteal phase for preventing ovarian hyperstimulation syndrome: A cross-sectional study. IJRM 2026; 24 (4) :337-348
URL: http://ijrm.ir/article-1-3798-en.html
URL: http://ijrm.ir/article-1-3798-en.html
Shiva Fayyazi Moghaddam1 
, Masoumeh Hajshafiha *2 , Tahereh Behroozi Lak1 , Sonia Sadeghpour3 , Arian Haghtalab4
, Masoumeh Hajshafiha *2 , Tahereh Behroozi Lak1 , Sonia Sadeghpour3 , Arian Haghtalab4
1- Department of Obstetrics and Gynecology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
2- Department of Obstetrics and Gynecology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. ,mhajshiafha@gmail.com; hajshafiha.m@umsu.ac.ir
3- Department of Obstetrics and Gynecology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. & Reproductive Health Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran.
4- School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. & School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
2- Department of Obstetrics and Gynecology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. ,
3- Department of Obstetrics and Gynecology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. & Reproductive Health Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran.
4- School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. & School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Abstract: (12 Views)
Background: Ovarian hyperstimulation syndrome (OHSS) is a severe iatrogenic disorder resulting from controlled ovarian stimulation. The administration of a gonadotropin-releasing hormone antagonist (cetrorelix) during the luteal phase is a practical approach for preventing OHSS.
Objective: This study aimed to evaluate the efficacy and safety of different cetrorelix regimens for preventing OHSS in high-risk groups.
Materials and Methods: In this cross-sectional study, data of 271 women with a high-risk profile for OHSS presented to the Infertility Center of Kosar hospital, Urmia, Iran from March 2023 and March 2025 and those who underwent intracytoplasmic sperm injection were extracted from their medical records. Participants were given prophylactic luteal-phase cetrorelix regimen of 0.5 mg twice daily (BID group, n = 101), 0.5 mg 3 times daily (TDS group, n = 38), or 0.75 mg TDS group (n = 102). After correcting for baseline characteristics, a logistic regression model determined independent hospitalization predictors. The primary outcomes measured in this study were the frequency and severity of OHSS and the rate of hospitalization due to OHSS. OHSS severity was graded according to standard classification, and hospitalization was defined as the need for inpatient management of OHSS. The study then compared these outcomes across the 3 different cetrorelix dosing regimens.
Results: OHSS frequency and severity decreased in a dose-dependent way, with no moderate or severe cases in the 0.75 mg TDS group (p < 0.001). Lower-dose groups had higher hospitalization rates than the 0.75 mg TDS reference group after adjusting for confounding variables. The likelihood was 20 times higher for the 0.5 mg TDS group (adjusted odds ratio = 19.92, 95% CI [1.99, 199.04]) and 79 times higher for the 0.5 mg BID group (adjusted odds ratio = 79.29, 95% CI [9.31, 675.43]).
Conclusion: In individuals with elevated risk, 0.75 mg TDS luteal-phase cetrorelix more effectively decreases OHSS risk and reduces hospitalizations compared to lower dosages.
Objective: This study aimed to evaluate the efficacy and safety of different cetrorelix regimens for preventing OHSS in high-risk groups.
Materials and Methods: In this cross-sectional study, data of 271 women with a high-risk profile for OHSS presented to the Infertility Center of Kosar hospital, Urmia, Iran from March 2023 and March 2025 and those who underwent intracytoplasmic sperm injection were extracted from their medical records. Participants were given prophylactic luteal-phase cetrorelix regimen of 0.5 mg twice daily (BID group, n = 101), 0.5 mg 3 times daily (TDS group, n = 38), or 0.75 mg TDS group (n = 102). After correcting for baseline characteristics, a logistic regression model determined independent hospitalization predictors. The primary outcomes measured in this study were the frequency and severity of OHSS and the rate of hospitalization due to OHSS. OHSS severity was graded according to standard classification, and hospitalization was defined as the need for inpatient management of OHSS. The study then compared these outcomes across the 3 different cetrorelix dosing regimens.
Results: OHSS frequency and severity decreased in a dose-dependent way, with no moderate or severe cases in the 0.75 mg TDS group (p < 0.001). Lower-dose groups had higher hospitalization rates than the 0.75 mg TDS reference group after adjusting for confounding variables. The likelihood was 20 times higher for the 0.5 mg TDS group (adjusted odds ratio = 19.92, 95% CI [1.99, 199.04]) and 79 times higher for the 0.5 mg BID group (adjusted odds ratio = 79.29, 95% CI [9.31, 675.43]).
Conclusion: In individuals with elevated risk, 0.75 mg TDS luteal-phase cetrorelix more effectively decreases OHSS risk and reduces hospitalizations compared to lower dosages.
Keywords: Cetrorelix, Gonadotropin-releasing hormone, Ovarian hyperstimulation syndrome, Sperm injections, Intracytoplasmic, Vascular endothelial growth factors.
Type of Study: Original Article |
Subject:
Assisted Reproductive Technologies
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
